stockrow
Saturday 7 November 2026
Export SYRA’s income statement to Excel — free account
Syra Health Corp.
SYRA Healthcare Medical Care Facilities
Syra Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.2 million, down 9.47% from fiscal 2024.
- Revenue
- +51.5%
- EPS
- +221.5%
- Free cash flow
- +235.8%
Quarter to September 2026, against a year earlier
0.80
0.07
−8.05%
Follow SYRA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 64.00 | 16.21 |
P/S ratio |
0.15 | 0.34 | 1.04 | 1.39 | |
P/FCF ratio |
0.00 | 3.50 | 81.00 | 18.36 | |
P/Operating CF |
(3.69) | 1.93 | (11.73) | 37.65 | |
P/B ratio |
0.51 | 1.11 | 3.20 | 4.13 | |
Price to Tangible BV |
0.51 | 1.11 | 3.20 | 4.13 | |
EV/Sales |
0.17 | 0.19 | 1.00 | 1.32 | |
EV/EBITDA |
0.00 | 0.00 | 95.88 | 19.40 | |
EV/Operating CF |
(2.70) | 1.93 | 73.51 | 17.30 | |
EV/FCF |
(2.66) | 1.95 | 77.46 | 17.44 | |
Quick Ratio |
3.75 | 2.40 | 3.00 | 3.25 | |
Current Ratio |
4.06 | 2.48 | 3.13 | 3.47 | |
Net Debt/EBITDA |
12.10 | (15.22) | (8.42) | (7.93) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
2.24 | 1.99 | 2.22 | 2.39 | |
Operating CF/Net income |
2.15 | 5.65 | (2.87) | 0.96 | |
Capex/Depreciation |
(0.04) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(31.56) | 76.40 | 114.36 | 214.29 | |
Research and Development Expense of Revenue |
0.01% | 0.30% | 1.98% | 1.83% | |
Selling, General and Administrative Expense of Revenue |
32.72% | 25.74% | 26.25% | 25.90% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.35% | 1.02% | 0.88% | 1.77% | |
Graham Net Nets |
1.93 | 0.89 | 0.30 | 0.24 | |
Graham Number |
0.00 | 0.00 | 0.21 | 0.51 | |
Earnings Yield |
(83.67%) | (6.95%) | 1.56% | 6.17% | |
Free Cash Flow Yield |
(42.49%) | 28.57% | 1.23% | 5.45% | |
Revenue per Share |
0.15 | 0.19 | 0.18 | 0.18 | |
Operating CF per Share |
(0.02) | 0.11 | (0.05) | 0.02 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | 0.11 | (0.05) | 0.02 | |
Cash per Share |
0.14 | 0.24 | 0.16 | 0.17 | |
Shareholders Equity per Share |
0.18 | 0.20 | 0.20 | 0.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.18 | 0.20 | 0.20 | 0.21 | |
Free Cash Flow |
(0.29) | 1.36 | (0.72) | 0.33 | |
Working Capital |
2.06 | 2.35 | 2.55 | 2.96 | |
Capital Expenditures |
0.00 | — | — | — | |
Net Current Asset Value |
2.06 | 2.35 | 2.55 | 2.96 | |
EV/EBIT |
0.00 | 0.00 | 107.95 | 19.55 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 112.88 | 20.58 | |
| Other line items | |||||
Average Receivables |
0.80 | 0.91 | 1.18 | 1.22 | |
Average Payables |
0.17 | 0.35 | 0.38 | 0.26 | |
Average Assets |
3.23 | 3.83 | 3.65 | 3.74 | |
Average Common Equity |
2.49 | 2.41 | 2.52 | 2.62 |
Columns are period end dates · fundamentals updated 5 Nov 2026